Obsidian Therapeutics Inc. (OBX) 12-Month Stock Forecast & Price Target Cone

The Roarable RQD rating assigns OBX a score of 34 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid," per the Roarable RQD rating. Across the five pillars, the fundamental cash engine scores 8 of 20 (ROIC -35%; FCF yield -10.09%), indicating that the business is not currently converting capital into positive returns or free cash flow. The whale/13F flow pillar scores 5 of 20, the insider conviction pillar scores 3 of 20, and the macro regime fit pillar scores 5 of 20 (beta 1.0; sector sensitivity). The forensic balance sheet pillar scores 13 of 20 (Altman Z 26; Piotroski F 2/9; Debt/Equity 0.5), which is the strongest pillar but still reflects weak fundamental quality on the Piotroski measure.

For a prospective investor, the practical reading is that the rating is weighted toward negative cash generation and weak ownership and insider signals, while the balance sheet offers some offset. The rating frames the stock as elevated-risk on fundamentals; any upside case must therefore rest on factors outside the reported cash engine, such as the macro liquidity signal discussed below. Valuation tradeoffs are difficult to assess directly because P/E, EPS, and EV/EBITDA are not available in source data, so the investor cannot benchmark the $896.9M market capitalization against earnings. This is an analytical summary of the source data and not personalized financial advice.

Obsidian Therapeutics Inc. (OBX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the profile. The company's products, customer base, and revenue model are not described in the source data. The FY 2025 and FY 2024 financials report revenue of $0.0M in each period, per the SEC financials. The profile does not describe how the company makes money.

Per the SEC financials, reported revenue was $0.0M in both periods, with operating losses of $-105.7M (FY 2025) and $-91.3M (FY 2024). Gross, operating, and net margins are each reported as 0% in the market data. ROIC is -35% and the FCF yield is -10.09%, per the market data. The Altman Z-Score is 26 and the Piotroski F-Score is 2/9, with Debt/Equity of 0.5, per the Roarable RQD rating. Cash declined from $49.8M to $40.4M across the two reported periods, per the SEC financials.

Per the recent news and catalysts section, the feed contains six items, all flagged YELLOW with impact label MARKET WIRE, sourced from Simply Wall St, BioSpace, TradingView, Nasdaq, Stock Titan, and MarketBeat. The headlines reference a Simply Wall St stock analysis, an announcement that the company will present updated Amsoki-cel (OBX-115) Phase 1/2 data in advanced melanoma at the SITC 2026 Annual Meeting, a TradingView estimates page, a Nasdaq closing bell event, a Stock Titan price page, and a MarketBeat item reporting that short interest rose 249.5% in September. The summaries for these items are generic and do not state the data contained in the presentation or the estimates.

The proprietary Butterfly signal is a LIQUIDITY_TAILWIND with a Macro Tailwind Score of 96/100, severity 94, direction BULLISH. The signal reports a True Net Liquidity Index of $5,745.73B, a -0.64% 4-week rate of change, a High-Yield OAS of +2 bps, and a rolling 5-year regression assigning OBX a 6.00x Net Liquidity beta (r = -0.58), per the Butterfly Supply-Chain Graph. Risk watch items include the 249.5% short-interest increase reported by MarketBeat and the negative cash-flow and ROIC readings in the financial sections.

• What products or therapies generate the company's economics, given that reported revenue is $0.0M in both periods?
• What are the P/E, forward P/E, EV/EBITDA, and EPS values needed to benchmark the $896.9M market capitalization against earnings?
• What is the company's debt position, since debt is reported as N/A in both periods despite a Debt/Equity ratio of 0.5?
• What do the Amsoki-cel (OBX-115) Phase 1/2 data show, and how do they bear on the cash-burn trajectory?
• What is the cash runway implied by $40.4M in cash against an FY 2025 FCF of $-90.5M?